RT Journal Article
T1 COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
A1 Martínez López, Joaquín
A1 De La Cruz, Javier
A1 Gil Manso, Rodrigo
A1 Alegre Amor, Adrián
A1 Ortiz, Javier
A1 Llamas, Pilar
A1 Martínez Díez, Yolanda
A1 Hernández Rivas, José Ángel
A1 González Gascón y Marín, Isabel
A1 Benavente Cuesta, Celina
A1 Estival Monteliu, Pablo
A1 Jiménez Yuste, Víctor
A1 Canales Albendea, Miguel Ángel
A1 Bastos Oreiro, Mariana Beatriz
A1 Kwon Kim, Mi
A1 Valenciano, Susana
A1 Callejas Charavia, Marta
A1 López Jiménez, Javier
A1 Herrera Puente, Pilar
A1 Duarte, Rafael
A1 Núñez Martín Buitrago, Lucía
A1 Sánchez Godoy, Pedro
A1 Jacome Yerovi, Cristina
A1 Martínez Barranco, Pilar
A1 García Roa, María
A1 Escolano Escobar, Cristian
A1 Matilla García, Arturo
A1 Rosado Sierra, Belén
A1 Aláez Usón, María Concepción
A1 Quiroz Cervantes, Keina
A1 Martínez Chamorro, Carmen
A1 Pérez Oteyza, Jaime
A1 Martos Martinez, Rafael
A1 Herráez, Regina
A1 González Santillana, Clara
A1 Del Campo, Juan Francisco
A1 Alonso, Arancha
A1 Fuente, Adolfo de la
A1 Pascual, Adriana
A1 Bustelos Rodriguez, Rosalía
A1 Sebrango, Ana
A1 Ruiz Mediavilla, Elena
A1 Marcheco-Pupo, Eriel Alexis
A1 Grande, Carlos
A1 Cedillo, Ángel
A1 Lumbreras Bermejo, Carlos Juan
A1 Arroyo Barea, Andrés
A1 Casas Rojo, Jose Manuel
A1 Calbacho Robles, Maria
A1 Díez Martín, José Luis
A1 García Suárez, Julio
AB Mortality rates for COVID-19 have declined over time in the general population, but data in patients with hematologic malignancies are contradictory. We identified independent prognostic factors for COVID-19 severity and survival in unvaccinated patients with hematologic malignancies, compared mortality rates over time and versus non-cancer inpatients, and investigated post COVID-19 condition. Data were analyzed from 1166 consecutive, eligible patients with hematologic malignancies from the population-based HEMATO-MADRID registry, Spain, with COVID-19 prior to vaccination roll-out, stratified into early (February–June 2020; n = 769 (66%)) and later (July 2020–February 2021; n = 397 (34%)) cohorts. Propensity-score matched non-cancer patients were identified from the SEMI-COVID registry. A lower proportion of patients were hospitalized in the later waves (54.2%) compared to the earlier (88.6%), OR 0.15, 95%CI 0.11–0.20. The proportion of hospitalized patients admitted to the ICU was higher in the later cohort (103/215, 47.9%) compared with the early cohort (170/681, 25.0%, 2.77; 2.01–3.82). The reduced 30-day mortality between early and later cohorts of non-cancer inpatients (29.6% vs. 12.6%, OR 0.34; 0.22–0.53) was not paralleled in inpatients with hematologic malignancies (32.3% vs. 34.8%, OR 1.12; 0.81–1.5). Among evaluable patients, 27.3% had post COVID-19 condition. These findings will help inform evidence-based preventive and therapeutic strategies for patients with hematologic malignancies and COVID-19 diagnosis.
PB MDPI
SN 2072-6694
YR 2023
FD 2023
LK https://hdl.handle.net/20.500.14352/72298
UL https://hdl.handle.net/20.500.14352/72298
LA eng
NO Martínez López, J., De La Cruz, J., Gil Manso, R. et al. «COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study». Cancers, vol. 15, n.o 5, febrero de 2023, p. 1497. DOI.org (Crossref), https://doi.org/10.3390/cancers15051497.
NO Fundación Madrileña de Hematología y Hemoterapia
NO Fundación Leucemia y Linfoma
NO Asociación Madrileña de Hematología y Hemoterapia
DS Docta Complutense
RD 1 may 2025